Breakthrough drugs spark call for PBS re-think

Australia needs to find a way to fund breakthrough drugs like the new generation of immune-activating cancer therapies,  says Professor Grant McArthur, head of translational research at the Peter MacCallum Cancer Centre in Melbourne.

Using unusually enthusiastic language, he describes the PD-1 inhibitors Pembrolizumab from Merck and nivolumab from Bristol-Myers Squibb as potential game changers.

“It’s a paradigm shift for melanoma treatment and very significant for the field of oncology.”

He says three trials presented at